These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 21505427)

  • 1. Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice.
    Yin H; Saleh AF; Betts C; Camelliti P; Seow Y; Ashraf S; Arzumanov A; Hammond S; Merritt T; Gait MJ; Wood MJ
    Mol Ther; 2011 Jul; 19(7):1295-303. PubMed ID: 21505427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
    Wang Q; Yin H; Camelliti P; Betts C; Moulton H; Lee H; Saleh AF; Gait MJ; Wood MJ
    J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B; Wood MJA; Roberts TC
    RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.
    Yin H; Moulton HM; Betts C; Seow Y; Boutilier J; Iverson PL; Wood MJ
    Hum Mol Genet; 2009 Nov; 18(22):4405-14. PubMed ID: 19692354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy.
    Cao L; Han G; Gu B; Yin H
    PLoS One; 2014; 9(11):e111079. PubMed ID: 25365558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
    Maruyama R; Yokota T
    Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse.
    Yin H; Betts C; Saleh AF; Ivanova GD; Lee H; Seow Y; Kim D; Gait MJ; Wood MJ
    Mol Ther; 2010 Apr; 18(4):819-27. PubMed ID: 20068555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results.
    van Putten M; Tanganyika-de Winter C; Bosgra S; Aartsma-Rus A
    Nucleic Acid Ther; 2019 Apr; 29(2):92-103. PubMed ID: 30672725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
    Echigoya Y; Yokota T
    Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy.
    Lim KRQ; Woo S; Melo D; Huang Y; Dzierlega K; Shah MNA; Aslesh T; Roshmi RR; Echigoya Y; Maruyama R; Moulton HM; Yokota T
    Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35193974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
    Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice.
    Yin H; Lu Q; Wood M
    Mol Ther; 2008 Jan; 16(1):38-45. PubMed ID: 17968354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
    McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
    Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice.
    Malerba A; Thorogood FC; Dickson G; Graham IR
    Hum Gene Ther; 2009 Sep; 20(9):955-65. PubMed ID: 19469709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
    Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
    Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
    Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
    Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice.
    Negishi Y; Ishii Y; Shiono H; Akiyama S; Sekine S; Kojima T; Mayama S; Kikuchi T; Hamano N; Endo-Takahashi Y; Suzuki R; Maruyama K; Aramaki Y
    Mol Pharm; 2014 Mar; 11(3):1053-61. PubMed ID: 24433046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy.
    Blain AM; Greally E; McClorey G; Manzano R; Betts CA; Godfrey C; O'Donovan L; Coursindel T; Gait MJ; Wood MJ; MacGowan GA; Straub VW
    PLoS One; 2018; 13(6):e0198897. PubMed ID: 29912990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.